

Policy Number	SUR705.010
Policy Effective Date	01/01/2026

Temporomandibular Joint Disorders

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
RX501.019: Botulinum Toxin
RX501.101: Orthopedic Applications of Platelet-Rich Plasma
SUR702.005: Acupuncture for Pain Management, Nausea and Vomiting and Opioid Dependence
SUR716.001: Cosmetic and Reconstructive Procedures
SUR717.001: Gender Assignment Surgery and Gender Reassignment Surgery with Related Services

Disclaimer

Carefully check state regulations and/or the member contract.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Legislative Mandates

EXCEPTION: For members residing in the state of Louisiana, R.S. 22:1055 requires coverage for diagnostic, therapeutic, or surgical procedures related to the temporomandibular joint (TMJ) and associated musculature and neurological conditions. Coverage may be subject to the same conditions, limitations, precertification, prior authorization, or referral procedures that apply to coverage for diagnostic, therapeutic, or surgical procedures involving other bones or joints of the human skeleton.

EXCEPTION (Illinois only): Illinois Public Act 103-0123 (IL HB 1384) Coverage for Reconstructive Services requires the following policies amended, delivered, issued, or renewed on or after January 1, 2025 (Individual and family PPO/HMO/POS; Student; Group [Small Group; Mid-Market; Large Group Fully Insured PPO/HMO/POS] or Medicaid), to provide coverage for medically necessary services that are intended to restore physical appearance on structures of the body damaged by trauma.

EXCEPTION: For members residing in the state of Arkansas, § 23-79-150 relating to musculoskeletal disorders of the face, neck, or head, requires coverage, when such coverage is elected by the group policyholder, for the medical treatment of musculoskeletal disorders affecting any bone or joint in the face, neck, or head, including temporomandibular joint disorder and craniomandibular disorder.

Treatment shall include both surgical and nonsurgical procedures. This coverage shall be provided for medically necessary diagnosis and treatment of these conditions whether they are the result of accident, trauma, congenital defect, developmental defect, or pathology. This applies to the following: Fully Insured Group, Student, Small Group, Mid-Market, Large Group, HMO, EPO, PPO, POS. Unless indicated by the group, this mandate or coverage will not apply to ASO groups.

EXCEPTION: For members residing in the state of Mississippi, §83-9-45 requires coverage for diagnostic and surgical treatment of temporomandibular joint disorder and craniomandibular disorder. Coverage for diagnostic services and surgery shall be the same as that for treatment to any other joint in the body and shall apply if the treatment is administered or prescribed by a physician or dentist. This applies to the following: Fully Insured Group, Small Group, Mid-Market, Large Group, HMO, EPO, PPO, POS.

EXCEPTION (Texas only): Title 8, Subtitle E, Chapter 1360, Section 002 (TIC 1360.002), provides benefits for dental, medical, or surgical expenses incurred as a result of a health condition, accident, or sickness, including: a group, blanket, or franchise insurance policy or insurance agreement, a group hospital service contract, or a group evidence of coverage that is offered by an insurance company. § TIC 1360.004 requires a health benefit plan that provides coverage for medically necessary diagnostic or surgical treatment of conditions affecting skeletal joints must provide comparable coverage for diagnostic or surgical treatment of conditions affecting the temporomandibular joint if the treatment is medically necessary as a result of: 1) an accident; 2) a trauma; 3) a congenital defect; 4) a developmental defect; or 5) a pathology. TIC 1360.005 does not require a health benefit plan to provide coverage for dental services if dental services are not otherwise scheduled or provided as part of the coverage provided under the plan. This applies to Fully Insured, PPO, HMO, POS, EPO.

Coverage

NOTE 1: Each benefit plan or contract defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply.

This medical policy does NOT address Gender Reassignment Services (Transgender Services). This medical policy IS NOT TO BE USED for Gender Reassignment Services. Refer to SUR717.001, Gender Assignment Surgery and Gender Reassignment Surgery with Related Services.

NOTE 2: The Coverage section is organized on the basis of diagnostic procedures, non-surgical treatment, and surgical treatment for temporomandibular joint (TMJ) disorders (TMJD, also known as TMD).

Diagnostic Procedures

Diagnostic procedures **may be considered medically necessary** when the individual has persistent symptoms of TMJD, including, but not limited to:

- Pain localized in the TMJ, the muscles of mastication, and/or the periauricular area, which may or may not be aggravated by chewing, jaw function, and/or mandibular movement (such as yawning);
- Noise in the TMJ with movement (e.g., clicking, grating, crepitus, and/or popping) that is accompanied by pain and/or decreased mobility, and is frequently audible by ear or can be heard with a stethoscope;
- Headache, jaw ache, and/or facial pain, often in combination with neck, shoulder or back pain;
- Limited and/or asymmetric mandibular movement;
- Locking of the jaw;
- Catching of the jaw on movement;
- Point tenderness on TMJ palpation;
- Signs of oral parafunction, such as bruxism (tooth grinding), e.g., abnormal occlusal wear.

For individuals who meet the above criteria, the diagnostic procedures that **may be considered medically necessary** in diagnosing TMJ include:

- Comprehensive physical examination with detailed history, which includes palpation of the myofascial muscles and jaw joint, measurements to assess any limitation of mouth opening, assessment of any noise in the jaw joint;
- Diagnostic x-ray, tomograms, and arthrograms;
- Computerized tomography (CT) or magnetic resonance imaging (MRI) (in general, CT scans and MRIs are reserved for pre-surgical evaluation);
- Cephalograms (x-rays of jaws and skull);
- Pantograms (x-rays of maxilla and mandible).

The following diagnostic procedures **are considered experimental, investigational, and/or unproven** in diagnosing TMJ disorders:

- Electromyography (EMG), including surface EMG;
- Kinesiology;
- Thermography;
- Neuromuscular junction testing;
- Somatosensory testing;
- Intra-oral tracing or gothic arch tracing (intended to demonstrate deviations in the positioning of the jaws that are associated with TMJ dysfunction);
- Muscle testing (other than testing included in the physician's physical examination);
- Range of motion measurements (other than measurements included in the physician's physical examination);
- Computerized mandibular scan (measures and records muscle activity related to movement and positioning of the mandible and is intended to detect deviations in occlusion and muscle spasms related to TMJD);
- Ultrasound imaging/sonogram;
- Arthroscopy of the TMJ for purely diagnostic purposes;
- Joint vibration analysis;

Treatment-Non-Surgical

The following non-surgical treatments of TMJD **may be considered medically necessary** for individuals who have persistent symptoms (see list under Diagnostic Procedures above) and have been diagnosed with TMJD:

- Physical therapy;
- Injection of joint spaces with local anesthetics or corticosteroids;
- Intra-oral reversible prosthetic devices and/or maxillomandibular (occlusal) appliances (encompassing fabrication, insertion, and adjustment); and/or
- Study models of the teeth when done in preparation for a covered splint or appliance, or when needed as preparation for a covered surgical procedure.

The following non-surgical treatments **are considered not medically necessary** for treatment of TMJ disorders:

- Orthodontics;
- Dental restorations, dental prostheses;

The following non-surgical treatments **are considered experimental, investigational, and/or unproven** for treatment of TMJ disorders:

- Electrogalvanic stimulation;
- Iontophoresis;
- Biofeedback;
- Ultrasound;
- Devices promoted to maintain joint range of motion and to develop muscles involved in jaw function;
- Any methods used to alter the vertical dimensions and/or change the occlusal or jaw relationship, including orthodontic services;
- Transcutaneous electrical nerve stimulation (TENS);
- Percutaneous electrical nerve stimulation (PENS);
- Platelet concentrates;
- Dextrose prolotherapy;
- Hyaluronic acid;
- Acupuncture; and/or
- Botulinum toxin A.

Treatment-Surgical

Surgical procedures performed on the temporomandibular joint **may be considered medically necessary** for individuals who have documented evidence of:

- Severe trauma; OR
- Pathology of the TMJ that has not responded to non-surgical, conservative, reversible treatment modalities, usually on long-term, chronic basis AND one or more of the following:
 - Continuous and/or repetitive episodes of pain and mechanical signs;
 - Significant clinical disability and/or loss in quality of life;

- Evidence of progression of disease by history and/or imaging studies.

In addition, surgical procedures performed on the jaw (i.e., orthognathic surgery) **may be considered medically necessary** when:

- The individual has met the above criteria; AND
- Documentation is provided that proves a positive relationship between the individual's long-term symptoms and a malocclusion and/or discrepancy in jaw alignment.

Surgical procedures that **may be considered medically necessary** for the treatment of TMJ that meet the above criteria include, but are not limited to:

- Orthognathic surgery, including, but not limited to:
 - LeFort I, midface reconstruction;
 - Mandibular reconstruction, with or without bone graft and/or internal rigid fixation; segmental osteotomy.
- Injections of the joint other than arthrocentesis;
- Manipulation for reduction of fracture or dislocation,
- Arthroscopic procedures, including, but not limited to:
 - Arthrocentesis;
 - Arthrolysis;
 - Debridement;
 - Disc manipulation/repositioning/fixation/release;
 - Abrasion arthroplasty; or
- Open surgical procedures, including, but not limited to:
 - Disc arthroplasty (repositioning, recontouring, fixation discopexy);
 - Condylectomy;
 - Meniscectomy (disc removal) without replacement, temporary alloplastic implant, or reconstruction with autogenous tissue graft;
 - Osseous recontouring (mandibular condyle, glenoid fossa, articular eminence);
 - Arthroplasty;
 - Joint reconstruction, with autogenous costochondral graft or prosthesis;
 - Open reduction, internal fixation of condylar fracture/dislocation;
 - Excision of tumor or bony hypertrophy/hyperplasia;
 - Mandibular/condylar repositioning (condylotomy and/or osteotomy);
 - Coronoidectomy, mandibular coronoidectomy;
 - Myotomy.

Genioplasty may sometimes be performed for cosmetic purposes. Please refer to Medical Policy SUR716.001 Cosmetic and Reconstructive Procedures.

Policy Guidelines

None.

Description

Temporomandibular Joint Disorder

Temporomandibular joint disorder (TMJD) refers to a group of disorders characterized by pain in the temporomandibular joint and surrounding tissues. Initial conservative therapy is generally recommended; there are also a variety of nonsurgical and surgical treatment possibilities for patients whose symptoms persist.

Diagnosis of Temporomandibular Joint Disorder

In the clinical setting, TMJD is often a diagnosis of exclusion and involves physical examination, patient interview, and a review of dental records. Diagnostic testing and radiologic imaging are generally only recommended for patients with severe and chronic symptoms. Diagnostic criteria for TMJD have been developed and validated for use in both clinical and research settings. (1-3)

Symptoms attributed to TMJD vary and include, but are not limited to, clicking sounds in the jaw; headaches; closing or locking of the jaw due to muscle spasms (trismus) or displaced disc; pain in the ears, neck, arms, and spine; tinnitus; and bruxism (clenching or grinding of the teeth).

Treatment

For many patients, symptoms of TMJD are short-term and self-limiting. Conservative treatments (e.g., eating soft foods, rest, heat, ice, avoiding extreme jaw movements) and anti-inflammatory medication are recommended before considering more invasive and/or permanent therapies (e.g., surgery).

Regulatory Status

Since 1981, several muscle-monitoring devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Some examples are the K7x Evaluation System (Myotronics), the BioEMG III™ (Bio-Research Associates), M-Scan™ (Bio-Research Associates), and the GrindCare Measure® (Medotech A/S). These devices aid clinicians in the analysis of joint sound, vibrations, and muscle contractions when diagnosing and evaluating TMJD. FDA product code: KZM.

Table 1. Muscle-Monitoring Devices Cleared by the U.S. Food and Drug Administration

Devices	Manufacturer	Date Cleared	510(k) No.	Indication
K7x Evaluation System	Myotronics, Inc	Nov 2000	K003287	Electromyography
BioEMG III™	Bio-Research Associates, Inc	Feb 2009	K082927	Electromyography, Joint Vibration Recording

GrindCare Measure	Medotech A/S	Apr 2012	K113677	Electromyography, Nocturnal Bruxism
M-Scan™	Bio-Research Associates	Jul 2013	K130158	Electromyography
TEETHAN 2.0	BTS S.P.A.	Dec 2016	K161716	Electromyography
GrindCare System	Sunstar Suisse S.A.	Sep 2017	K163448	Electromyography, Sleep Bruxism
Nox Sleep System	Nox Medical	Nov 2019	K192469	Electromyography, Sleep Bruxism

No: number.

Rationale

Medical policies assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

For treatment of temporomandibular joint disorders (TMJD), literature searches have focused on studies comparing novel treatments with conservative interventions and/or placebo controls (rather than no-treatment control groups) and reporting pain reduction and/or functional outcome improvements (e.g., jaw movement).

Diagnosis of Temporomandibular Joint Disorder

Clinical Context and Test Purpose

TMJD (also known as temporomandibular joint syndrome) refers to a cluster of problems associated with the temporomandibular joint and musculoskeletal structures. The etiology of TMJD remains unclear and is believed to be multifactorial. TMJD is often divided into 2 main categories: articular disorders (e.g., ankylosis, congenital or developmental disorders, disc derangement disorders, fractures, inflammatory disorders, osteoarthritis, joint dislocation) and masticatory muscle disorders (e.g., myofascial pain, myofibrotic contracture, myospasm, neoplasia).

The purpose of specific diagnostic tests in individual who have suspected TMJD is to provide an option that is an alternative to or an improvement on existing diagnostic approaches, such as a comprehensive history and physical exam and alternative diagnostic tests.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with suspected TMJD.

Interventions

The diagnostic tests being considered are ultrasound, surface electromyography, and joint vibration analysis.

Comparators

The following practice is currently being used to diagnose TMJD: a comprehensive history and physical exam and alternative diagnostic tests. Alternative diagnostic tests can include routine dental x-rays, panoramic radiographs, computed tomography, magnetic resonance imaging (MRI), and scintigraphy.

Outcomes

The general outcomes of interest are test validity and other test performance measures. The existing literature evaluating ultrasound, surface electromyography, and joint vibration analysis as diagnostic tests for suspected TMJD has varying lengths of follow-up. While studies described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, at least 1 year of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria

For the evaluation of clinical validity, studies that meet the following eligibility criteria were considered:

- The study population represents the population of interest. Eligibility and selection are described.
- The test is compared with a credible reference standard.
- If the test is intended to replace or be an adjunct to an existing test; it should also be compared with that test.

- Studies should report sensitivity, specificity, and predictive values. Studies that completely report true- and false-positive results are ideal. Studies reporting other measures (e.g., Receiver Operating Characteristic, Area Under the Receiver Operating Curve, c-statistic, likelihood ratios) may be included but are less informative.
- Studies should also report reclassification of diagnostic or risk category.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Systematic Reviews

Ultrasound

Almeida et al. (2019) evaluated the diagnostic efficacy of ultrasound to assess TMJDs such as disc displacement (DD), joint effusion (JE), and condylar changes, with 3D imaging as the reference standard (Table 2). (4) The authors identified 28 studies with a total of 2829 joints. Combined sensitivities of ultrasound for diagnosing DD, JE, and condylar changes all fell within the “acceptable” range as defined by the authors. “Excellent” combined specificity was reported for ultrasound to diagnose JE, but specificity for DD was in the “acceptable” range, and condylar changes specificity fell below acceptable. Heterogeneity across studies was high (I^2 range, 83.35 to 96.12), as were the ranges of sensitivity and specificity seen across studies. The variation in the sensitivity and specificity across the 3 pathologies could be related to the diagnostic parameters used to detect the TMJD, or it could be due to the different transducer frequencies used, probe design, examination methods, and skill of the sonographers and image readers. Considering the limitations and cost of MRI, the lower cost, accessibility, and non-invasive and non-ionizing radiation of ultrasound make it a good screening method, especially for DD and JE. Future studies should be conducted to determine if dynamic 3D ultrasound with high-resolution transducer increases the reliability of the examination.

Tables 2 and 3 summarize the results of the meta-analysis by Almeida et al. (2019). (4)

Table 2. Characteristics of Systematic Review and Meta-Analysis of Studies Assessing Ultrasound to Diagnose Temporomandibular Joint Disorder

Study	Dates	Trials	Participants	N (Range)	Design	Reference Standards
Almeida et al. (2019) (4)	1997-2016	28	Patients with suspected TMJ disc displacement, joint effusion, or condylar changes	1204 (3 to 100)	27 cohort; 1 case-control	MRI or CT imaging

CT: computed tomography; MRI: magnetic resonance imaging; TMJ: temporomandibular joint.

Table 3. Summary of Combined Sensitivity and Specificity of Ultrasound to Diagnose Temporomandibular Joint Disorder

Almeida et al. (2019) (4)	Combined Sensitivity ¹			Combined Specificity ²		
	Percent	95% CI	Range, %	Percent	95% CI	Range, %
TMJD						
DD	79	70 to 87	22 to 95	85	76 to 91	17 to 97
JE	70	52 to 84	20 to 84	96	45 to 100	53 to 100
CC	73	50 to 88	15 to 94	72	63 to 80	20 to 100

CI: confidence interval; CC: condylar change; DD: disc displacement; JE: joint effusion; TMJD: temporomandibular joint disorder.

¹ Acceptable sensitivity defined by authors as 70% to 80%; excellent sensitivity as >80%.

² Acceptable specificity defined by authors as 80% to 90%; excellent specificity as >90%.

A literature review by Manfredini et al. (2009) included 20 studies evaluating ultrasound for diagnosing TMJDs; all studies evaluated DD, and several also considered osteoarthritis and/or joint effusion. (5) The reported sensitivity of ultrasound to detect DD, compared with the reference standard (MRI in most studies), ranged from 31% to 100%, and the specificity ranged from 30% to 100%. Reviewers stated that even when changes in ultrasound technology over time were taken into account, study findings were contradictory. The reviewers noted unexplained differences between studies conducted by the same group of researchers. Reviewers concluded that additional advances are needed to standardize the ultrasound assessment of TMJD before it can be considered an accurate diagnostic tool.

Surface Electromyography

A review on surface electromyography by Klasser et al. (2006) found a lack of literature on the accuracy of this method of diagnosis, compared with a criterion standard (i.e., comprehensive clinical examination and history-taking). (6) Reviewers concluded there was insufficient evidence that electromyography can accurately distinguish people with facial pain from those without pain, but that the technique may be useful in a research setting.

Joint Vibration Analysis

Sharma et al. (2013) published a systematic review on joint vibration analysis for diagnosis of TMJDs. (7) Reviewers identified 15 studies that evaluated the reliability and/or diagnostic accuracy of joint vibration analysis compared with a reference standard. Methodologic limitations were identified in all studies and included the absence of well-defined diagnostic criteria, use of a non-validated system for classifying disease progression, variability within studies in the reference standard used, and lack of blinding. In the 14 studies reporting on diagnostic accuracy, there was a wide range of reported values, with sensitivity ranging from 50% to 100% and specificity ranging from 59% to 100%.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from RCTs.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Section Summary: Diagnosis of Temporomandibular Joint Disorder (TMJD)

Current evidence is insufficient or imprecise to support the use of ultrasound, surface electromyography, or joint vibration analysis to diagnose TMJD.

Orthotics and Pharmacologic Treatment of Temporomandibular Joint Disorder

Clinical Context and Therapy Purpose

The purpose of orthotics and treatment in individuals with a confirmed diagnosis of TMJD is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as alternative nonsurgical intervention.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with confirmed TMJD.

Interventions

The therapies being considered are intraoral devices or appliances and treatment. Intraoral devices and appliances are described in the Regulatory Status section above and can include stabilization splints. Nonsurgical treatment can include nonsteroidal anti-inflammatory drugs, opioids, corticosteroids, muscle relaxants, antidepressants, anticonvulsants, and benzodiazepines.

Comparators

The following therapies are currently being used for the treatment of TMJD: alternative nonsurgical interventions, such as medications, physical therapy, and injections. Alternative medicine techniques can also be used, such as acupuncture, relaxation techniques, transcutaneous electric nerve stimulation (TENS), and biofeedback.

Outcomes

The general outcomes of interest are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Symptoms of TMJD may include pain, tenderness, or aching in the jaw or 1 or both of the temporomandibular joints, difficulty or pain while chewing, and locking of the temporomandibular joint.

The existing literature evaluating intraoral devices or appliances and treatment as a treatment for confirmed TMJD has varying lengths of follow-up, ranging from 6 weeks to 1 year. Although the systematic reviews described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, at least 1 year of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

List and Axelsson (2010) published a review of systematic reviews on treatments for TMJD published through August 2009. (8) They identified 30 reviews; there were 23 qualitative systematic reviews and 7 meta-analyses. Eighteen of the systematic reviews included only RCTs, three only included case-control studies, and nine included a mix of RCTs and case series. TMJDs were defined inconsistently in the primary studies and systematic reviews, and several reviews addressed the related diagnoses of bruxism, disc replacements, and myofascial pain. Twenty-nine of the systematic reviews had pain intensity or pain reduction as the primary outcome measure, and 25 reported clinical outcome measures such as jaw movement or jaw tenderness on palpation. Reviewers divided the treatments into 5 categories (some studies were included in >1 category). These categories and the main findings are listed in Table 4.

Table 4. Categories of Treatment

Categories	Number of Articles	Findings
Occlusal appliances, occlusal adjustment, and orthodontic treatment	10	Six systematic reviews did not find significant benefit vs other treatment, 4 found no benefit vs a placebo device, and 3 found occlusal therapy was better than no treatment.
Physical treatments including acupuncture,	8	Four reviews found no significant benefit of acupuncture over other treatments, 1 found no difference between acupuncture and placebo treatment, and 3 found acupuncture was better

TENS, exercise, and mobilization		than no treatment. One review found active exercise and postural training were effective for treating TMJD-related pain.
Pharmacologic treatment	7	Treatments found to be superior to placebo were analgesics (2 reviews), clonazepam or diazepam (3 reviews), antidepressants (4 reviews), and hyaluronate (1 review). One review found effects of hyaluronate and corticosteroids to be similar.
Maxillofacial surgery	4	Three reviews evaluated surgery for patients with disc displacements and 1 addressed orthognathic surgery in patients with TMJD. Reviews of surgical treatments generally included lower-level evidence (e.g., case series), and did not always compare surgery with a control condition. One review of patients with disc displacements with reduction reported similar treatment effects for arthrocentesis, arthroscopy, and discectomy, and another review in patients in disc displacement without reduction found similar effects of arthrocentesis, arthroscopy, and physical therapy (used as a control intervention). Due to the lack of high-quality controlled studies, conclusions could not be drawn about intervention equivalence.
Behavioral therapy and multimodal treatments	6	Two reviews found biofeedback to be better than active control or no treatment, 1 review found a combination of biofeedback and CBT to be better than no treatment, and 2 found a combination of biofeedback and relaxation to be better than no treatment. One review found the effects of biofeedback and relaxation to be similar.

Adapted from List and Axelsson (2010) (8)

CBT: cognitive-behavioral therapy; TENS: transcutaneous electrical nerve stimulation; TMJD: temporomandibular joint disorders.

Overall, reviewers concluded that there was insufficient evidence that electrophysical modalities and surgery would be effective for treating TMJD. They found some evidence that occlusal appliances, acupuncture, behavioral therapy, jaw exercises, postural training, and some medications could be effective at reducing pain for patients with TMJDs. However, reviewers noted that most of the systematic reviews examined included primary studies with considerable variation in methodologic quality and, thus, it was not possible to draw definitive conclusions about the effectiveness of any of the treatments.

Yao et al. (2023) published a systematic review and network meta-analysis of therapies for TMJD-associated chronic pain. (9) A total of 153 trials (N=8713) evaluating 59 interventions (or combinations of interventions) were included. Three interventions were considered to be most effective for pain relief based on moderate certainty evidence: manual trigger point therapy, cognitive behavioral therapy with biofeedback or relaxation, and therapist-assisted jaw mobilization. Four interventions were considered to probably improve physical function: supervised jaw exercises/stretching, manipulation, acupuncture, and supervised jaw exercise/

mobilization. The certainty of evidence for orthotics and all included pharmacologic treatments was considered low to very low. This network meta-analysis served as the evidence base for 2023 clinical practice guidelines.

Orthotics

Intraoral Devices or Appliances

Friction et al. (2010) reported on a systematic review of RCTs on the intraoral treatment of TMJDs and identified 47 publications on 44 trials. (10) Intraoral appliances included soft and hard stabilization appliances, anterior positioning appliances, anterior bite appliances, and soft resilient appliances. Studies compared 2 types of devices or compared 1 device with different treatments (e.g., acupuncture or biofeedback). None of the studies evaluated the use of 1 device during the day and a different device during the night. The primary outcome of the meta-analysis was pain reduction. The pain was measured differently in the studies, and reviewers defined a successful outcome as at least a 50% reduction in pain on a self-report scale or at least an “improved” status when the pain was measured by the subjective report of status. Ten RCTs were included in 2 meta-analyses; the others were excluded because they did not measure pain, there were not at least 2 studies using similar devices or control groups, or data were not usable for pooled analysis. A pooled analysis of 7 RCTs (n=385) that evaluated hard stabilization appliances and use of palatal non-occluding appliances as a control found a significantly greater reduction in pain with hard appliances (odds ratio, 2.45; 95% confidence interval [CI], 1.56 to 3.86; $p<.001$). A pooled analysis of 3 studies (n=216) did not find a statistically significant effect of hard appliances compared with a no-treatment control group (odds ratio, 2.14; 95% CI, 0.80 to 5.75; $p=.12$).

Ivorra-Carbonell et al. (2016) reported on a systematic review of functional advancement devices for TMJD, which included systematic reviews, meta-analyses, RCTs, case-control studies, and cohort studies, assessed using PRISMA methodology. (11) Reviewers included 21 articles evaluating some advancement device, considered of medium or high quality by CONSORT criteria. Results were summarized descriptively; reviewers concluded that, after treatment with mandibular advancement, the condyle was in a “more advanced position.”

Randhawa et al. (2016) published a systematic review of noninvasive interventions for TMJDs, which included RCTs with at least 30 individuals per treatment arm, cohort studies with at least 100 patients per exposed group, and case-control interventions. (12) Reviewers identified 31 studies for appraisal, of which 7 RCTs described in 8 publications had a low risk of bias and were assessed further. Most RCTs evaluated interventions outside the scope of our review, including cognitive-behavioral therapy and self-care management. Three RCTs evaluated occlusal devices for TMJDs of variable duration and generally reported no significant improvements with occlusal devices regarding pain, mouth opening, or other outcomes.

A 2024 Cochrane systematic review evaluated RCTs of occlusal devices in patients with TMJD. (13) A total of 57 studies with 2846 participants compared occlusal splints (primarily full hard stabilization splint) with other treatment, placebo, or no treatment. There was no significant difference in self-reported joint pain when chewing between occlusal splints and placebo or

therapy, but the evidence is very uncertain. Occlusal splints reduced muscle pain when chewing compared to no treatment but had little to no effect when compared to low-level laser or acupuncture (very uncertain evidence). The authors determined there is insufficient evidence for the effectiveness of occlusal intervention despite inclusion of nearly 3000 participants, and further research must have a large enough sample to provide meaningful results with long-term follow-up.

Stabilization Splints – Systematic Reviews

Ebrahim et al. (2012) identified 11 RCTs comparing splint therapy for TMJDs with minimal or no therapy. (14) Nine of the 11 studies used stabilization splints, 1 used soft splints, and 1 used an anterior repositioning appliance. Reviewers used the GRADE system to rate study quality. Nine studies did not report whether allocation was concealed, and 6 studies did not report masking outcome assessors. Length of follow-up in the studies ranged from 6 to 52 weeks. A pooled analysis of study findings found that splint therapy was significantly associated with a reduction in reported pain compared with minimal or no intervention (standardized mean difference [SMD], -0.93; 95% CI, -1.33 to -0.53). Using a 100-millimeter visual analog scale (VAS) to measure pain, splint therapy was associated with an 11.5 mm lower mean VAS score (95% CI, 16.5 to -6.6 mm). There were no statistically significant differences between groups in quality of life or depression scores.

Zhang et al. (2016) identified 13 publications from 11 studies (N=538) evaluating splint therapy for TMJDs. (15) Risk of bias was high for 2 or more domains for all studies. Splint therapy group patients had greater improvements in pain control than control patients (mean difference, 2.02; 95% CI, 1.55 to 2.49; $I^2=0.558$).

A systemic review of 37 RCTs by Riley et al. (2020) revealed a lack of evidence that splints reduce pain (SMD, -0.18; 95% CI, -0.42 to 0.06) when all subtypes of TMJD were pooled into 1 global TMJD group. (16) The result was based on 13 trials (N=1076). The included trials used different splint types and varied in outcome measures used, and the evidence was rated as of low-certainty.

Al-Moraissi et al. (2020) performed a network meta-analysis of 48 RCTs to determine the effectiveness of various occlusal splints for TMJD. (17) Compared with controls, an anterior repositioning splint (low quality evidence), counseling with a hard stabilization splint (low quality evidence), mini-anterior splint (very low quality evidence), and hard stabilization splint (low quality evidence) decreased pain in patients with arthrogenous TMJD. Compared with controls, a mini-anterior splint (very low quality evidence), soft stabilization splint (very low quality evidence), counseling therapy alone (moderate quality evidence), and counseling with hard stabilization splint (moderate quality evidence) decreased pain intensity in patients with myogenous TMJDs.

Zhang et al. (2021) conducted a systematic review and meta-analysis of 6 RCTs (N=498) that compared exercise therapy and occlusal splint therapy for painful TMJD. (18) The analysis found similar efficacy between the 2 treatments for the major outcomes of interest: pain reduction

(SMD, -0.29; 95% CI, -0.62 to 0.04; $p=.08$; $I^2=51\%$) and maximum mouth opening range (SMD, 0.12; 95% CI, -0.24 to 0.48; $p=.51$; $I^2=40\%$).

Stabilization Splints – Randomized Controlled Trials (RCT)

An RCT by Alajbeg et al. (2020) enrolled 34 patients with chronic TMJD who received a stabilization splint or placebo splint. (19) At 3-month follow up, patients receiving a stabilization splint experienced improvement in pain intensity ($p=.009$), depressive symptoms ($p=.011$), and oxidant/antioxidant ratio ($p=.018$) compared with placebo. The number of disability days and pain-free mouth opening were similar between the 2 groups at 3 months. At 6 months (post-treatment follow up period), stabilization splints significantly reduced the number of disability days compared to placebo ($p=.023$).

An RCT by Melo et al. (2020) compared an occlusal splint, manual therapy, counseling, and the combination of an occlusal splint and counseling for managing pain and anxiety in 89 patients with TMJD. (20) After 1 month, all interventions reduced pain and anxiety compared with baseline, with all 4 groups showing similar changes.

Ram et al. (2021) conducted an RCT ($N=160$) that compared the effect of muscle energy technique, occlusal splint therapy, and their combination. (21) All participants (including a control group) received education on self-management and counseling. At 3 months, all groups experienced reduction in pain compared to baseline ($p<.001$ for all treatments vs. placebo), but there was no difference between treatments. At the same timepoint, mouth opening was only significantly improved from baseline in patients who received muscle energy technique and combination therapy.

Stabilization Splints – Observational Study

An observational study by Tonlorenzi et al. (2019) assessed 21 patients with TMJD, specifically myofascial pain, to determine the effectiveness of wearing a “high” oral splint (vs. a “low” oral splint) for 3 months while sleeping. (22) Results showed a significant increase of the interocclusal distance as measured by kinesiograph (from 0.64 ± 0.53 mm to 1.42 ± 0.76 mm; $p<.001$), accompanied by a reduction in pain intensity in oral and extraoral regions after the 3 months.

Pharmacologic Treatment – Systematic Reviews

Häggman-Henrikson et al. (2017) published a systematic review that included 41 RCTs assessing various pharmacologic regimens for pain from TMJDs or burning mouth syndrome; of these, 13 were selected for a network meta-analysis. (23) Nine studies evaluated temporomandibular muscular pain, which appeared to decrease more with cyclobenzaprine than with placebo, although no specific statistics were reported. Pain reduction was also favorable for botulinum toxin and Ping-On ointment in the meta-analysis; other descriptive analyses showed a reduction of pain with nonsteroidal anti-inflammatory drugs and melatonin tablets when compared to placebo.

Mena et al. (2020) reported a systematic review and meta-analysis of 9 RCTs comparing topical products to placebo or control interventions for managing pain from TMJD. (24) Topical nonsteroidal anti-inflammatory drugs showed similar outcomes to placebo. In 1 study, Theraflex-TMJ cream (methyl salicylate as active ingredient) significantly decreased pain scores at 10 days ($p=.003$) and at follow-up ($p=.027$) compared to placebo. In 1 study, Ping On ointment (18% peppermint oil, 20% menthol) reduced pain at 4 weeks of application ($p<.001$) but not after 7 days of use ($p=.136$). In another study, cannabidiol ointment improved pain intensity compared to placebo ($p<.001$). Overall, the authors concluded that evidence is of low quality due to a small number of studies and biases within the included studies.

Machado et al. (2020) evaluated the effectiveness of botulinum toxin type A (BTX-A) for TMJD in a systematic review and meta-analysis of 12 RCTs. (25) At month 1, BTX-A reduced pain more effectively compared with placebo (mean difference, -1.74 points; 95% CI, -2.94 to -0.54; 3 RCTs [$n=60$]). But at months 3 and 6, BTX-A reduced pain to a similar level as placebo. The authors concluded that the quality of evidence is low, and the results do not support the use of BTX-A for managing pain due to TMJD.

Pharmacologic Treatment – Randomized Controlled Trials (RCTs)

In their multicenter, double-blind RCT, Isacsson et al. (2019) assessed the pain reduction efficacy of a single-dose, intra-articular injection of methylprednisolone (1 mL) to the temporomandibular joint. (26) A total of 54 patients with unilateral TMJD were randomized to receive either the methylprednisolone ($n=27$) or saline ($n=27$). Pain levels at maximum jaw opening were recorded on a VAS (1 to 100) before the injections and 4 weeks after. The per-protocol analysis showed VAS scores for the methylprednisolone group decreased from a mean of 61.0 (95% CI, 50.0 to 70.7) to 33.9 (95% CI, 21.6 to 46.2); the saline group VAS score decreased from a mean of 59.6 (95% CI, 50.7 to 65.9) to 33.9 (95% CI, 23.8 to 43.9). The differences in these scores were statistically insignificant ($p=.81$). In addition, the methylprednisolone group experienced twice as many adverse events as the saline group.

Tchiveileva et al. (2020) evaluated the efficacy of propranolol hydrochloride extended-release versus placebo in reducing pain from TMJD. (27) Two hundred patients with chronic TMJD were randomized to receive either 10 weeks of the drug ($n=100$) or placebo ($n=99$). The primary outcome was change in the Weekly Mean Pain Index after 9 weeks of treatment (index range, 0 to 100; higher score, worse outcome). The least-squares mean of the propranolol group was -13.9 (95% CI, -17.4 to -10.5); for the placebo group it was -12.1 (95% CI, -15.5 to -8.7), a nonsignificant difference ($p=.41$).

Section Summary: Orthotics and Pharmacologic Treatment

Evidence evaluating the use of orthotics in the treatment of TMJD, while sometimes conflicting and inconclusive, suggests that use of orthotics may reduce TMJD pain. One systematic review of intraoral appliances (44 studies) and meta-analyses of subsets of these studies found a significant benefit of intraoral appliances compared with control interventions. Several studies, meta-analyses, and systematic reviews exploring the effectiveness of stabilization splints on TMJD pain revealed conflicting results. Overall, the evidence shows that stabilizing splints may

improve pain and positively impact depressive and anxiety symptoms. The evidence related to pharmacologic treatment varies because individual studies, systematic reviews, and meta-analyses lack consistency in evaluating specific agents. Some systematic reviews have found a significant benefit of several pharmacologic treatments (e.g., analgesics, muscle relaxants, and anti-inflammatory medications [vs. placebo]), but other studies showed a lack of benefit with agents such as methylprednisolone and BTX-A.

Other Nonsurgical Therapies

Clinical Context and Therapy Purpose

The purpose of nonsurgical therapies in individuals with a confirmed diagnosis of TMJD is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as alternative nonsurgical intervention.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with confirmed TMJD.

Interventions

The nonsurgical therapies being considered are acupuncture, biofeedback, TENS, orthodontic services, hyaluronic acid (HA), platelet concentrates, and dextrose prolotherapy.

Comparators

The following therapy is currently being used to make decisions about the treatment of TMJD: alternative nonsurgical intervention, such as medications.

Outcomes

The general outcomes of interest are symptoms, functional outcomes, quality of life, and treatment-related morbidity.

The existing literature evaluating nonsurgical therapies as a treatment for confirmed TMJD has varying lengths of follow-up, ranging from 1 week to 6 months. Although the systematic reviews and RCTs described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, at least 1 year of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

- Studies with duplicative or overlapping populations were excluded.

Acupuncture – Systematic Reviews

A systematic review and meta-analysis by Jung et al. (2011) identified 7 sham-controlled randomized trials evaluating acupuncture for treating TMJD. (28) The studies included a total of 141 patients. Sample sizes of individual studies ranged from 7 to 28 patients. Four studies used a single acupuncture session, and the other 3 used 6 to 12 sessions. All 7 studies reported a change in pain intensity as assessed by VAS. In 6 of the studies, pain intensity was measured immediately after treatment; the seventh measured pain after 16 weeks. A pooled analysis of findings from 5 studies (n=107) found a statistically significant reduction in pain intensity, as measured by VAS. The pooled weighted mean difference in pain intensity was -13.63 (95% CI, -21.16 to -6.10; $p<.001$). A pooled subgroup analysis of 4 studies (n=89) found acupuncture to be superior to a nonpenetrating sham acupuncture (weighted mean difference, -13.73; 95% CI, -21.78 to -5.67; $p<.001$). A pooled analysis of 2 studies (n=18) did not find a significant difference in efficacy between acupuncture and a penetrating sham acupuncture (weighted mean difference, -12.95; 95% CI, -34.05 to 8.15; $p=.23$). The latter analysis might have been underpowered. Reviewers noted that previous studies had found that a 24.2-mm change in pain assessed by a 100-mm VAS represents a clinically significant difference and that only 2 of the selected studies had a change of 24.2 mm or more.

Liu et al. (2021) conducted a systematic review and meta-analysis of 10 RCTs (N=670) that used warm needle acupuncture for the treatment of TMJD. (29) In this analysis, acupuncture was more effective than several other treatments (including acupuncture alone, drug therapy, and ultrasonic therapy) in achieving an effective rate (relative risk [RR], 1.20; 95% CI, 1.06 to 1.35; $p=.003$; $I^2=71\%$) and cure rate (RR, 1.82; 95% CI, 1.46 to 2.28; $p<.00001$; $I^2=8\%$).

Park et al. (2023) included 22 RCTs (N=471) in a meta-analysis evaluating acupuncture for adults with TMJD. (30) The effective rate was improved with acupuncture (RR, 1.19; 95% CI, 1.12 to 1.27; $p<.00001$; $I^2=66\%$) compared with active controls (e.g., physical therapy, pharmacologic therapy, splinting). However, pain (mean difference, -0.41; 95% CI, -0.91 to 0.10; $p=.12$; $I^2=40\%$) and maximum mouth opening (mean difference, 1.05; 95% CI, -2.36 to 4.46; $p=.55$; I^2 not assessed as information based on 1 trial) were not different between groups. The quality of evidence was low to very low.

Hyaluronic Acid (HA) Injection – Systematic Reviews

Several systematic reviews of studies have assessed the use of HA for treating TMJDs. Three reviews without meta-analysis found benefits to the use of HA. The review by Manfredini et al. (2010) included 19 papers that dealt with HA to treat either temporomandibular joint DD or inflammatory-degenerative disorders. Eight of the studies were RCTs. All studies reported decreased pain levels, and positive outcomes were maintained over the varying follow-up periods (range, 15 days to 24 months). The better outcomes with HA were shown only against placebo saline injections, but outcomes were similar to those seen with corticosteroid injections or oral appliances. (31) Results of a review of 9 RCTs by Machado et al. (2012) showed that intra-articular injections with corticosteroids and HA were effective in controlling

TMJD in the short and medium terms. In addition, results indicated that in the short-term, intra-articular injections with only HA had similar results to injections with corticosteroids; however, in the long-term, HA was more effective. (32) From the 8 studies included in their systematic review, Goiato et al. (2016) found that intra-articular injections of HA used in temporomandibular joint arthrocentesis are beneficial, but other drugs, such as corticosteroids and non-steroidal anti-inflammatory drug injections are also satisfactory options. (33)

Liu et al. (2017) conducted a systematic review and meta-analysis of RCTs or cohort studies that compared temporomandibular osteoarthritis outcomes in patients treated with intra-articular corticosteroid, hyaluronate, or placebo injection. (34) All 8 selected studies were RCTs; of these, 3 contained data on hyaluronate injection. Compared to placebo, corticosteroid injections prompted a significant decrease in long-term (i.e., ≥ 6 months post-procedure) pain (3 studies; mean difference, -0.74; 95% CI, -1.34 to -0.13; $p=.02$; $I^2=0\%$). However, in a pooled analysis of 2 studies (both of which included pretreatment arthrocentesis), long-term maximal mouth opening was increased for placebo more than for corticosteroid injection (mean difference, -2.06; 95% CI, -2.76 to -1.36; $p<.001$; $I^2=28\%$). Only 2 studies were available for comparing corticosteroid with hyaluronate injections, which precluded strong analysis. Short-term pain and mouth opening measures did not significantly differ between any of the injection groups, nor did the incidence of adverse events. The meta-analysis was limited by the small sample sizes of included trials, as well as by the variety of corticosteroid types used. Reviewers concluded that corticosteroid injection following arthrocentesis may be effective for relief of long-term joint pain but may be less effective for improving mouth opening.

Hyaluronic Acid Injections – Randomized Controlled Trials

Most published RCTs evaluating HA for treating TMJDs have had small sample sizes, short follow-up times, and/or lacked blinding. Representative RCTs with larger sample sizes and stronger methodology are described next.

Gorrela et al. (2017) reported on the efficacy of injecting sodium hyaluronate in patients with TMJDs. (35) The trial comprised 62 individuals with the disorder; some members ($n=31$) of the trial were treated with arthrocentesis, and some members ($n=31$) were treated by a combination of arthrocentesis and an injection of sodium hyaluronate. Follow-up was observed at 1 week, 2 weeks, 1 month, 3 months, and at 6 months. Using a VAS, patients were asked to measure pain from 1 to 10. Pain decreased significantly for patients in both treatment groups ($p<.001$) at the 1-week and the 6-month follow-up; however, patients who were injected with sodium hyaluronate reported a significantly stronger decrease in pain at the 6-month follow-up ($p<.001$). Pre-operative mean VAS pain scores for patients who received injection started at 6.0; by the 6-month follow-up, the mean VAS pain score was 0.23. Preoperative mean pain scores for patients who received arthrocentesis alone started at 6.77; by the 6-month follow-up, the mean pain score was 1.71. While not an overwhelmingly significant difference, the trialists concluded that adding an injection of sodium hyaluronate to arthrocentesis treatment can significantly decrease the pain felt by patients with TMJD.

A study by Manfredini et al. (2012) in Italy randomized 72 patients with TMJD to 1 of 6 treatment groups: 1) single-session arthrocentesis alone; 2) single-session arthrocentesis plus corticosteroid; 3) single-session arthrocentesis plus low-molecular-weight HA; 4) single-session arthrocentesis plus high-molecular-weight HA; 5) 5 weekly arthrocenteses plus low-molecular-weight HA; or 6) 5 weekly single-needle arthrocenteses plus low-molecular-weight HA. (36) Sixty (83%) of 72 participants completed the study, with between 9 and 12 patients per treatment group. In a per-protocol analysis, there were no significant differences among groups on any of the outcome variables at the 3-month follow-up. For example, the percentage change in pain at rest ranged from -29.1% in the group receiving 5 weekly single-needle arthrocentesis plus low-molecular-weight HA injections to -38.4% in the group receiving a single-session of arthrocentesis alone. Trial limitations included the small number of patients in each treatment group and the substantial number of dropouts in the absence of an intention-to-treat analysis.

A study by Bjornland et al. (2007) in Norway evaluated 40 patients with osteoarthritis of the TMJ in a double-blind RCT. (37) Patients received 2 injections, 14 days apart, of sodium hyaluronate or corticosteroids. The pain was assessed using a VAS ranging from 0 to 100. Patients were followed for 6 months (assessed at 14 days, 1 month, and 6 months). There was a statistically significant reduction in pain within each group at all follow-up points. At the 6-month follow-up, pain intensity (mean VAS score) was 14 in the HA group and 31 in the corticosteroid group; the between-group difference was statistically significant ($p < .001$). The number of patients who were pain-free at 6 months was 7 (35%) of 20 in the HA group and 6 (30%) of 20 in the corticosteroid group (p -value not reported).

Bertolami et al. (1993) published a double-blind placebo-controlled trial that evaluated 121 patients with TMJD. (38) Patients had a confirmed diagnosis of degenerative joint disease, reducing displaced disc or nonreducing displaced disc, failure of other nonsurgical treatments, and severe dysfunction. Patients received a single injection of sodium hyaluronate or saline and were followed for 6 months. Eighty patients were randomized to the hyaluronate group and 41 to the placebo group. This included 57 patients in the degenerative joint disease group, 50 patients in the reducing displaced disc group, and 14 patients in the nonreducing displaced disc group. Fourteen (12%) of 121 patients were excluded from the analysis because they did not meet eligibility criteria. Seven outcomes were assessed, including 3 measures of dysfunction, 2 measures of patient perception of improvement, and 2 measures of change in noise. No significant differences in outcomes were seen for the degenerative joint disease group. In the nonreducing displaced disc group, there were significant between-group differences through 1-month, favoring the HA group. The number of patients in the nonreducing displaced disc group who completed follow-up after 1 month was insufficient to draw meaningful conclusions about efficacy. The most consistent between-group differences in the reducing displaced disc group were for the 2 measures of patient perception of improvement and 1 of the noise variables. There were fewer between-group differences in dysfunction measures.

Hyaluronic Acid vs. Platelet-Rich Plasma – Systematic Reviews

Li et al. (2023) conducted a systematic review and meta-analysis comparing platelet-rich plasma with adjunctive HA as in arthrocentesis. (39) The analysis of 7 RCTs ($N=243$) failed to find

differences between groups in maximum mouth opening at 1 month (mean difference, 0.21; 95% CI, -1.29 to 1.70), 3 months (mean difference, 0.92; 95% CI, -2.96 to 4.80), or 6 months (mean difference, -0.05; 95% CI, -2.08 to 1.97). Pain scores were similar between groups through 6 months (mean difference, 0.06; 95% CI, -0.92 to 1.04). The analysis is limited by high heterogeneity ($I^2 \geq 81\%$), small sample sizes of the individual trials, and lack of placebo comparator.

Xu et al. (2023) conducted a network meta-analysis of 12 RCTs comparing HA, platelet-rich plasma, and platelet-rich fibrin with or without arthrocentesis in patients (N=421) with TMJD. (40) Platelet-rich plasma was determined to be the most effective agent for pain through 6 months; however, it was only significantly better than placebo (mean difference, -1.17; 95% CI, -1.82 to -0.51) and not other active treatments. For the outcome of maximum mouth opening, platelet-rich fibrin was significantly better than platelet-rich plasma (mean difference, -11.01; 95% CI, -16.17 to -5.86), HA (mean difference, 8.72; 95% CI, 3.64 to 13.80), and placebo (mean difference, 11.12; 95% CI, 6.45 to 15.79) at 6 months. Although there was low risk of bias, limitations of the analysis included inconsistency and imprecision.

Al-Hamed et al. (2021) compared platelet concentrates with HA or saline/Ringer's solution for treating patients with temporomandibular osteoarthritis in a systematic review and meta-analysis of 9 RCTs (N=407). (41) Compared with HA, platelet concentrates decreased pain VAS scores by -1.11 (95% CI, -1.62 to -0.60; $p < .0001$) at 3 months and by -0.57 (95% CI, -1.55 to 0.41; $p = .26$) at 12 months. Compared with saline, platelet concentrates decreased pain VAS scores by -1.33 (95% CI, -2.61 to -0.06; $p = .04$) at 3 months and -2.71 (95% CI, -4.69 to -0.72; $p = .008$) at 12 months. For maximum mouth opening, platelet concentrates had similar outcomes compared with HA and improved outcomes compared with saline at 3 months (2.9 mm; 95% CI, 1.47 to 4.3; $p < .0001$) and 6 months (1.69 mm; 95% CI, 0.13 to 3.25; $p = .03$).

Hyaluronic Acid vs. Platelet-Rich Plasma – Randomized Controlled Trials

Liu et al. (2023) randomized 70 patients with temporomandibular joint osteoarthritis to HA or platelet-rich plasma at a single center in China. (42) The HA group received 2 treatments given 2 weeks apart while the platelet-rich plasma group received a single injection. Numerous VAS scores including maximum VAS, mean VAS, sleeping VAS, and opening VAS were compared between groups; however, the only significant difference between groups was greater improvement on VAS opening at 1 month with platelet-rich plasma (VAS improvement, 2.42 vs 1.00; $p = .037$). Maximum mouth opening was greater with platelet-rich plasma at 1 month (4.39 vs 1.28; $p = .005$), 3 months (7.03 vs 2.38; $p = .004$), and 6 months (9.12 vs 3.72; $p = .002$). The study is limited by lack of blinding of the patient and treatment administrator.

Dasukil et al. (2022) conducted a double-blind RCT in 90 patients undergoing arthrocentesis for temporomandibular osteoarthritis. (43) Patients were randomized to 2 doses of platelet-rich plasma, HA alone, or control upon completion of arthrocentesis. The groups had similar VAS scores with the exception of platelet-rich plasma recipients having significantly improved pain at 6 months vs control (1.7 vs 3.3; $p < .001$). Mouth opening was significantly improved with platelet-rich plasma at all timepoints compared with control. Hyaluronic acid significantly

improved mouth opening at 6 months compared with control. No significant differences between HA and platelet-rich plasma were found.

In their randomized trial, Gokçe Kuyuk et al. (2019) compared platelet-rich plasma, HA, and intra-articular corticosteroids to treat patients with temporomandibular joint pain and those diagnosed with temporomandibular osteoarthritis. (44) Patients were evaluated in 2 groups: those who felt pain on lateral palpation (n=31) and those who felt pain on posterior palpation (n=43). The patients were then randomized to receive either platelet-rich plasma, HA, or corticosteroids. Temporomandibular joint pain (using a 5-point VAS), the presence of crepitation, loss of function, and loss of strength were assessed before treatment and monthly for 3 months following treatment. For patients who had lateral temporomandibular joint pain, statistically significant VAS score changes were seen in the platelet-rich plasma and HA groups ($p < .0028$ for both groups). In terms of crepitation, function, and strength, some changes were observed in the platelet-rich plasma, HA, and corticosteroids groups, but they were not statistically significant ($p > .0028$). For patients with posterior temporomandibular joint pain, the VAS scores showed significant improvements for platelet-rich plasma, HA, and corticosteroids ($p < .0028$ for all groups). Some improvements were found in crepitation, function, and strength, but they were not significant. Overall, all 3 treatments significantly improved palpation pain, but the greatest improvement was with platelet-rich plasma.

Hyaluronic Acid Plus Platelet-Rich Plasma – Randomized Controlled Trials

Hegab et al. (2023) conducted a single center, single-blind RCT in 90 patients undergoing arthrocentesis for temporomandibular osteoarthritis. (45) Patients were randomized to platelet-rich plasma alone, HA alone, or the combination of HA and platelet-rich plasma upon completion of arthrocentesis. Combination treatment generally had significantly greater maximum mouth opening than single-agent treatment throughout 12 months post-operative with the exception of similar outcomes between platelet-rich plasma and combination at 12 months (41.4 mm vs 41.9 mm). Significantly lower VAS scores were found in patients treated with combination treatment than either single agent therapy. VAS scores were lower with HA than platelet-rich plasma at 1, 3, and 6 months, but at 12 months, platelet-rich plasma resulted in lower VAS versus HA. The small sample size, lack of blinding, and lack of placebo group are notable limitations of this study.

Prolotherapy – Systematic Reviews

Sit et al. (2021) conducted a systematic review and meta-analysis of 5 RCTs that compared the efficacy of hypertonic dextrose prolotherapy injections to placebo in patients with TMJD. (46) The primary outcome, pain intensity as measured by VAS, was improved with dextrose prolotherapy compared to placebo at 12 weeks (3 studies, n=89; SMD, -0.76; 95% CI, -1.19 to -0.32; $I^2 = 0\%$). No differences were seen between treatments in maximum mouth opening or temporomandibular joint dysfunction.

Prolotherapy – Randomized Controlled Trials

Haggag et al. (2022) conducted an RCT comparing the efficacy of 25% dextrose prolotherapy injections to saline solution injections in 30 patients with bilateral disc displacement (N=60

joints) due to TMJD. (47) Outcomes measured included pain intensity (measured by VAS), maximum mouth opening, and joint sounds. Patients were evaluated at 1 week after each injection, and 3 months and 6 months after the last injection. The average number of dextrose injections per session for each patient was 3.4. Patients who received dextrose injections had significantly lower pain at 1 week after the fourth injection ($p=.015$), 3 months after the last injection ($p<.001$), and 6 months after the last injection ($p<.001$) compared to those who received saline injections. Additionally, maximum mouth opening was significantly greater in those who received dextrose injections at 1 week post each injection (post-injection 1 $p=.002$; post-injection 2 $p=.001$; post-injection 3 $p=.005$; post-injection 4 $p=.041$), 3 months after the last injection ($p<.001$), and 6 months after the last injection ($p<.001$) compared to those in the saline group. There was no significant difference in joint sounds at any timepoint between groups. Patients in the dextrose group reported higher satisfaction scores at 6 months compared to patients receiving saline injections ($p<.001$).

Section Summary: Nonsurgical Therapies

The evidence on acupuncture is limited by the small number of studies, small sample sizes, and in most studies, efficacy assessment only immediately posttreatment. The evidence on the use of HA to treat TMJD is inconclusive, given the methodologic issues with the systematic reviews and RCTs conducted (e.g., small sample sizes) and better surgical options. Limited evidence suggests that platelet concentrates and dextrose prolotherapy may improve TMJD pain. No reliable evidence is available for biofeedback, TENS, or orthodontic services for TMJD.

Surgical Techniques

Clinical Context and Therapy Purpose

The purpose of surgical techniques in individuals with a confirmed diagnosis of TMJD is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as nonsurgical intervention.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with confirmed TMJD.

Interventions

The surgical therapies being considered are arthrocentesis and arthroscopy.

Comparators

The following therapies are currently being used to make decisions about treatment of TMJD: alternative nonsurgical intervention, such as intraoral devices and appliances, treatment, acupuncture, biofeedback, TENS, orthodontic services, and HA.

Outcomes

The general outcomes of interest are symptoms, functional outcomes, quality of life, and treatment-related morbidity.

The existing literature evaluating surgical techniques as a treatment for confirmed TMJD has varying lengths of follow-up of up to 6 months. While the systematic reviews described below all reported at least 1 outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, at least 6 months of follow-up is considered necessary to demonstrate efficacy.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

In a systematic review, Vos et al. (2013) identified 3 RCTs (N=222) that compared the efficacy of lavage of the temporomandibular joint (i.e., arthrocentesis or arthroscopy) with nonsurgical temporomandibular joint treatment. (48) Although reviewers assessed the quality of the studies to be adequate, only one stated that allocation to treatment group was concealed; 2 did not explicitly state use of an intention-to-treat analysis. The 2 primary outcomes considered were change in pain and maximal mouth opening at 6 months compared to baseline. The pain was measured by VAS. Pooled analysis of data from the 3 trials found a statistically significant reduction in pain at 6 months with surgery plus lavage versus nonsurgical therapy (SMD, -1.07; 95% CI, -1.38 to -0.76). There was no statistically significant difference in the efficacy between the 2 treatments for the other outcome variable, maximal mouth opening (SMD, 0.05; 95% CI, -0.33 to 0.23).

In a network meta-analysis, Al-Moraissi et al. (2020) compared different treatment options (placebo/control; muscle exercises and occlusal splint therapy; splint therapy alone; intraarticular injection of HA or corticosteroid; arthrocentesis with or without HA, corticosteroid, and platelet-rich plasma; arthroscopy with or without HA and platelet-rich plasma; open joint surgery; physiotherapy) for arthrogenous TMJD in 36 RCTs for reducing pain and 33 RCTs for improving maximum mouth opening. (49) For short-term follow up of at most 5 months, injections of HA (SMD, -2.8; 95% CI, -3.7 to -1.8) and corticosteroids (SMD, -2.11; 95% CI, -2.9 to -1.2) achieved greater pain control compared with placebo/control. For follow up of at least 6 months and longer, arthroscopy with platelet-rich plasma (SMD, -3.5, 95% CI, -6.2 to -0.82), arthrocentesis with platelet-rich plasma (SMD, -3.08; 95% CI, -5.44 to -0.71), arthroscopy with HA (SMD, -3.01; 95% CI, -5.8 to -0.12), temporomandibular joint surgery (SMD, -3; 95% CI, -5.7 to -0.28), injection with HA (SMD, -2.9; 95% CI, -4.9 to -1.09), arthroscopy-alone (SMD, -2.6; 95% CI, -5.1 to -0.07) and arthrocentesis with HA (SMD, -2.3; 95% CI, -4.5 to -0.18) significantly improved pain compared with placebo/control. For improving maximum mouth opening,

various arthroscopy procedures (with and without platelet-rich plasma and HA injections) followed by arthrocentesis with platelet-rich plasma or HA were the most efficacious treatment approaches. Treatments such as occlusal splint therapy, physical therapy, muscle exercises with occlusal splint therapy, and placebo/control yielded the lower quality outcomes for reducing pain and improving maximum mouth opening. Most of the evidence included in the network meta-analysis was rated as low-quality or very low-quality, except the evidence for arthrocentesis with HA injections was of moderate quality.

Hu et al. (2023) conducted meta-analyses to compare arthrocentesis to conservative therapies such as analgesic, splints, or lifestyle modifications in individuals with TMJD. (50) Seven RCTs and 1 quasi-RCT were included. Analyses demonstrated that at 1 month and 6 months, but not at 3 months, arthrocentesis used as a first line treatment significantly reduced pain scores in individuals compared to conservative therapies. They found no difference in maximal mouth opening between arthrocentesis and conservative therapy groups at 1 month, 3 months, or 6 months.

Thorpe et al. (2023) compared arthrocentesis to conservative treatment in a meta-analysis of RCTs. (51) A total of 7 RCTs (N=448) evaluated pain (VAS) and maximum mouth opening at 6 months. Conservative management was variable among the trials, but the majority (n=6) included occlusal splints as part of the conservative treatment plan. Maximum mouth opening was improved with arthrocentesis, but pain scores were not significantly different between groups. Significant heterogeneity was found among the studies resulting in wide confidence intervals. Differences in conservative treatments may have contributed to this finding. Irrigation solutions and volumes of these solutions also contributed to variability in the arthrocentesis procedures among the RCTs.

Tables 5 and 6 include descriptive information on these reported systematic reviews and Table 7 reports results for each.

Table 5. Comparison of Studies Included in Systematic Reviews & Meta Analyses on Surgical Techniques

Study	Vos et al. (2013) (48)	Al-Moraissi et al. (2020) (49)	Hu et al. (2023) (50)	Thorpe et al. (2023) (51)
Stegenga et al. (1993)	●	●		
Fridrich et al. (1996)		●		
Goudot et al. (2000)		●		
Carmeli et al. (2001)		●		
Holmlund (2001)		●		

Minakuchi et al. (2001)		●		
Shi et al. (2002)		●		
Venancio et al. (2005)		●		
Bjørnland et al. (2007)		●		
Ismail (2007)		●		
Politi et al. (2007)		●		
Schiffman et al. (2007)	●	●		
Dıraçoğlu et al. (2009)	●		●	●
Haketa et al. (2010)		●		
Antônio et al. (2012)		●		
Craane et al. (2012)		●		
Huddleston Slater et al. (2012)		●		
Manfredini et al. (2012)		●		
Sahlström et al. (2013)			●	
de Carli et al. (2013)		●		
Vos et al. (2014)			●	●
Gencer et al. (2014)		●		
Tabrizi et al. (2014)		●		
Cömert Kiliç et al. (2015)		●		
Hanc et al. (2015)		●		
Hegab et al. (2015)		●		
Cömert Kiliç (2016)		●		

Fernández Sanromán et al. (2016)		●		
Korkmaz et al. (2016)		●		
Patel and Idrees (2016)		●		
Bouloux et al. (2017)		●		
Fernández-Ferro et al. (2017)		●		
Gorrela et al. (2017)		●		
Gurung et al. (2017)		●		
Ozdamar et al. (2017)		●		
Tatli et al. (2017)		●	●	●
Hosgor et al. (2017)			●	●
Yapici-Yavuz et al. (2018)		●		
Isacsson et al. (2019)		●		
Bergstrand et al. (2019)		●		
Ohrnell Malekzadeh et al. (2019)		●	●	●
Abbasgholizadeh et al. (2020)				●
Altaweel et al. (2021)			●	
Ritto et al. (2022)			●	●

Table 6. Systematic Reviews & Meta Analyses on Surgical Techniques Characteristics

Study	Dates	Trials	Trial/Patient inclusion	N (Range)	Design	Duration
Vos et al. (2013) (48)	1993-2009	3	Trials comparing lavage to nonsurgical	222 (21 to 120)	RCTs	6 month follow-up

			therapy for the treatment of TMJ arthropathy were included			
Al-Moraissi et al. (2020) (49)	1996-2019	36	Adults with arthrogenous TMJDs based on institution protocol or clear diagnosis including signs and symptoms of TMJD involved in studies comparing 2 or more of the following treatments were included: (1) conservative (splint, exercise, and self-care), (2) physical therapy (manual, low-laser), (3) HA, (4) corticosteroid, (5) arthrocentesis, (6) arthrocentesis plus HA, (7) arthroscopy, (8) arthrocentesis plus growth factors, (9) arthrocentesis plus	NR	RCTs	1 week to 4 years

			corticosteroids, (10) arthroscopy with growth factor, (11) arthroscopy with HA, (12) open joint surgery, (13) control			
Hu et al. (2023) (50)	2009-2022	8	Patients with any TMJD in studies comparing arthrocentesis to conservative, non-invasive therapy (ie, analgesics, splints, exercises, diet modifications)	395 (20 to 110)	RCTs and 1 quasi-RCT	up to 12 months
Thorpe et al. (2023) (51)	Through May 2022	7	Patients with any TMJD in studies comparing arthrocentesis to conservative therapy	448 (24 to 120)	RCTs	6 month follow-up

HA: hyaluronic acid; NR: not reported; RCT: randomized controlled trial; TMJD: temporomandibular joint disorders; TMJ: temporomandibular joint.

Table 7. Systematic Reviews & Meta Analyses on Surgical Techniques Results

Study	Change in pain from baseline	Maximal mouth opening
Vos et al. (2013) (48)		
Total N	222	222
Pooled SMD (95% CI)	-1.07 (-1.38 to -0.76)	0.05 (-0.33 to 0.23)
I^2 (p)	0.0%	0.0%
Al-Moraissi et al. (2020) (49)		
Total N	36 studies	33 trials
Short-term (≤ 5 months) vs. control/placebo		

Arthroscopy alone, pooled SMD (95% CI)	NS	1.70 (0.50 to 2.91)
Arthroscopy with growth factor, pooled SMD (95% CI)	NS	2.62 (0.87 to 4.36)
Arthroscopy with HA, pooled SMD (95% CI)	NS	2.31 (0.81 to 3.82)
Intermediate-term (≥6 months) vs. control/placebo		
Arthroscopy with growth factor, pooled SMD (95% CI)	-3.5 (-6.2 to -0.82)	3.22 (1.72 to 4.72)
Arthrocentesis with growth factor, pooled SMD (95% CI)	-3.08 (-5.44 to -0.71)	1.73 (0.44 to 3.02)
Arthroscopy with HA, pooled SMD (95% CI)	-3.01 (-5.8 to -0.12)	3.05 (1.62 to 4.47)
Open TMJ surgery, pooled SMD (95% CI)	-3.95 (-5.7 to -0.28)	NS
Corticosteroids, pooled SMD (95% CI)	-2.97 (-4.90 to -1.05)	2.11 (0.70 to 3.52)
Arthroscopy alone, pooled SMD (95% CI)	-2.6 (-5.1 to -0.07)	2.75 (1.40 to 4.11)
Arthrocentesis with HA, pooled SMD (95% CI)	-2.3 (-4.5 to -0.18)	1.53 (0.36 to 2.70)
HA, pooled SMD (95% CI)	NS	2.23 (1.16 to 3.29)
Arthrocentesis with corticosteroids, pooled SMD (95% CI)	NS	1.55 (0.29 to 2.81)
Arthrocentesis alone, pooled SMD (95% CI)	NS	1.41 (0.26 to 2.55)
Hu et al. (2023) (50)		
1 month vs. conservative treatment		
Total N	321	321
SMD (95% CI)	-0.82 (-1.43 to -0.20)	-0.06 (-3.67 to 3.54)
I^2 (p)	56% (.06)	88% (<.00001)
3 months vs. conservative treatment		
Total N	336	336
SMD (95% CI)	-0.66 (-1.68 to 0.37)	-0.35 (-3.95 to 3.25)
I^2 (p)	82% (<.0001)	89% (<.00001)
6 months vs. conservative treatment		
Total N	291	291
SMD (95% CI)	-1.38 (-2.45 to -0.32)	0.00 (-3.34 to 3.34)
I^2 (p)	86% (<.0001)	86% (<.0001)
Thorpe et al. (2023) (51)		
6 months vs. conservative treatment		

Total N	448	448
SMD (95% CI)	-1.09 (-2.19 to 0.01)	1.12 (0.45 to 1.78)
I ² (p)	100% (<.00001)	87% (<.00001)

CI: confidence interval; HA: hyaluronic acid; NS: not significant; SMD: standardized mean difference; TMJ: temporomandibular joint.

Observational Study

In a retrospective cohort study, Hossameldin and McCain (2018) assessed the efficacy of an office-based temporomandibular joint arthroscopic technique. The researchers assessed the following outcomes of the procedure: improvement in painless range-of-motion in the mandible, reduced pain on loading, and improvement in functional jaw pain. The cohort included an initial 363 patients, excluded 41, and an analysis was performed on the joints of the remaining 322 that were compromised. Within the 322 patients, 452 joints were operated on with a 66.6% (n=301 joints) success rate (p=.001). It is stated within the outcome variable section that the primary outcome variable of success or failure was determined by the reduction of joint pain postoperatively. This could be subjective. When the operation failed (n=151 joints, 33.3%), 141 joints were involved in a subsequent procedure that ranged from more advanced arthroscopy to a total joint replacement. (52)

Section Summary: Surgical Techniques

Meta-analyses of RCTs have reached conflicting conclusions regarding the efficacy of surgical techniques in patients with TMJD. Two recent meta-analyses each identified RCTs comparing arthrocentesis to various conservative management strategies. At 6 months, one analysis found improved maximum mouth opening with arthrocentesis while the other found similar outcomes between arthrocentesis and conservative treatments. Similarly, pain was improved with arthrocentesis in one analysis, but not the other. However, a 2020 network meta-analysis did find various arthroscopic procedures to be the most efficacious treatment approach for patients with TMJD.

Summary of Evidence

For individuals with suspected temporomandibular joint disorder (TMJD) who receive ultrasound, surface electromyography, or joint vibration analysis, the evidence includes systematic reviews of diagnostic test studies. Relevant outcomes are test validity and other performance measures. None of the systematic reviews found that these diagnostic techniques accurately identified patients with TMJD, and many of the studies had methodologic limitations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with a confirmed diagnosis of TMJD who receive intraoral devices or appliances or pharmacologic treatment, the evidence includes randomized controlled trials (RCTs) and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A systematic review of intraoral appliances (44 studies) and meta-analyses of subsets of these studies found a significant benefit of intraoral appliances compared with control interventions. Several studies, meta-analyses, and systematic reviews

exploring the effectiveness of stabilization splints on TMJD pain revealed conflicting results. Overall, the evidence shows that stabilizing splints may improve pain and positively impact depressive and anxiety symptoms. The evidence related to pharmacologic treatment varies because studies, systematic reviews, and meta-analyses lack consistency in evaluating specific agents. Some systematic reviews have found a significant benefit of several pharmacologic treatments (e.g., analgesics, muscle relaxants, and anti-inflammatory medications [vs. placebo]), but other studies showed a lack of benefit with agents such as methylprednisolone and botulinum toxin type A. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with a confirmed diagnosis of TMJD who receive acupuncture, biofeedback, transcutaneous electric nerve stimulation, orthodontic services, hyaluronic acid, platelet concentrates, or dextrose prolotherapy, the evidence includes RCTs, systematic reviews of these RCTs, and observational studies. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Systematic reviews evaluating acupuncture for TMJD have found inconsistent improvement in outcomes compared with sham or active controls. A 2023 meta-analysis of 22 RCTs failed to find improved pain or maximum mouth opening with acupuncture compared with active controls. Systematic reviews evaluating hyaluronic acid have found similar outcomes to corticosteroids or placebo. Platelet-rich plasma has been compared with hyaluronic acid in a number of systematic reviews and RCTs, but the studies are small and have methodologic limitations. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with a confirmed diagnosis of TMJD who receive arthrocentesis or arthroscopy, the evidence includes RCTs, systematic reviews of RCTs, and observational studies. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One review, which included 3 RCTs, compared arthrocentesis or arthroscopy with nonsurgical interventions for TMJD. Pooled analyses of the RCTs found that arthrocentesis and arthroscopy resulted in superior pain reduction compared with control interventions. A network meta-analysis, which included 36 RCTs, revealed that arthroscopy and arthrocentesis improve pain control and maximum mouth opening. Two recent meta-analyses identified RCTs comparing arthrocentesis to various conservative management strategies. At 6 months, one analysis found improved maximum mouth opening with arthrocentesis while the other found similar outcomes between arthrocentesis and conservative treatments. Similarly, pain was improved with arthrocentesis in one analysis, but not the other. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American Association for Dental, Oral, and Craniofacial Research (AADOCR)

In a 2010 (reaffirmed in 2015) the American Association for Dental Research (now the AADOCR) policy statement, recommended the following for the diagnosis and treatment of temporomandibular joint disorders (TMJDs) (53):

“It is recommended that the differential diagnosis of TMDs [temporomandibular disorders] or related orofacial pain conditions should be based primarily on information obtained from the

patient's history, clinical examination, and when indicated, TMJ [temporomandibular joint] radiology or other imaging procedures. The choice of adjunctive diagnostic procedures should be based upon published, peer-reviewed data showing diagnostic efficacy and safety. However, the consensus of recent scientific literature about currently available technological diagnostic devices for TMDs is that except for various imaging modalities, none of them shows the sensitivity and specificity required to separate normal subjects from TMD patients or to distinguish among TMD subgroups...."

"It is strongly recommended that, unless there are specific and justifiable indications to the contrary, treatment of TMD patients initially should be based on the use of conservative, reversible and evidence-based therapeutic modalities. Studies of the natural history of many TMDs suggest that they tend to improve or resolve over time. While no specific therapies have been proven to be uniformly effective, many of the conservative modalities have proven to be at least as effective in providing symptomatic relief as most forms of invasive treatment...."

American Society of Temporomandibular Joint Surgeons (ASTMJS)

In 2001, the ASTMJS issued consensus clinical guidelines focused on TMJDs associated with internal derangement and osteoarthritis. (54) For diagnosis of this type of TMJDs, a detailed history and, when indicated, a general physical examination was recommended. Imaging of the temporomandibular and associated structures was also recommended. Options for basic radiography to provide information on temporal bone and condylar morphology included the use of plain films, panoramic films, and tomograms. Also recommended was imaging of the disc and associated soft tissue with magnetic resonance imaging (MRI) or arthrography. Other diagnostic procedures indicated included computed tomography, MRI, arthrography (for selected cases) and isotope bone scans.

Nonsurgical treatment was recommended as first-line therapy for all symptomatic patients with this condition. Recommended treatment options included a change in diet, nonsteroidal anti-inflammatory drugs, maxillomandibular appliances, physical therapy, injections of corticosteroids or botulinum toxin, and behavior modification. If adequate symptom relief did not occur within 2 to 3 weeks, surgical consultation was advised. The guideline stated the following surgical procedures were considered accepted and effective for patients with TMJDs associated with internal derangement or osteoarthritis:

- Arthrocentesis;
- Arthroscopy;
- Condylotomy;
- Arthrotomy (prosthetic joint replacement may be indicated in selected patients who have severe joint degeneration, destruction, or ankylosis);
- Coronoidotomy/coronoidectomy;
- Styloidectomy.

BMJ Rapid Recommendations

The BMJ Rapid Recommendations panel developed guidelines for the management of patients with chronic pain (≥ 3 months) associated with TMJD. (55) The international expert panel included representation from an academic center in the United States.

The panel favored the following therapies:

- Cognitive behavior therapy (strong recommendation);
- Therapist-assisted mobilization (strong recommendation);
- Manual trigger point therapy (strong recommendation);
- Supervised postural or jaw exercise (strong recommendation);
- Usual care including home exercises, stretching, reassurance, and education (strong recommendation);
- Manipulation (conditional recommendation);
- Supervised jaw exercise with mobilization (conditional recommendation);
- Cognitive behavior therapy with non-steroidal anti-inflammatory drugs (conditional recommendation);
- Manipulation with postural exercise (conditional recommendation);
- Acupuncture (conditional recommendation).

The panel recommended against the following therapies:

- Reversible occlusal splints (conditional recommendation);
- Arthrocentesis (conditional recommendation);
- Cartilage supplement with or without hyaluronic acid injection (conditional recommendation);
- Low level laser therapy (conditional recommendation);
- Transcutaneous electrical nerve stimulation (conditional recommendation);
- Gabapentin (conditional recommendation);
- Botulinum toxin (conditional recommendation);
- Hyaluronic acid (conditional recommendation);
- Relaxation therapy (conditional recommendation);
- Trigger point injection (conditional recommendation);
- Acetaminophen (conditional recommendation);
- Topical capsaicin (conditional recommendation);
- Biofeedback (conditional recommendation);
- Corticosteroid injection (conditional recommendation);
- Benzodiazepines (conditional recommendation);
- Beta-blockers (conditional recommendation);
- Irreversible oral splints (strong recommendation);
- Discectomy (strong recommendation);
- Non-steroidal anti-inflammatory drugs with opioids (strong recommendation).

American Association of Oral and Maxillofacial Surgeons (AAOMS) (2023)

The AAOMS 2023 Parameters of Care: Clinical Practice Guidelines for Oral and Maxillofacial Surgery (Temporomandibular Joint Surgery) state that temporomandibular joint (TMJ) surgery is indicated for the treatment of a wide range of pathologic conditions. (56) The guideline details indications for therapy, therapeutic goals, and specific factors affecting risk, therapeutic parameters, and outcome assessment indices for multiple conditions. The authors' state that surgical intervention for internal derangement arthritic conditions, degenerative joint disease infectious arthritis and ankylosis/restricted jaw motion is indicated only when nonsurgical therapy has been ineffective, and pain and/or dysfunction are moderate to severe.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 8.

Table 8. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
NCT06573502	Assessment of Platelet Rich Plasma With Injectable Platelet Rich Fibrin VS Platelet Rich Plasma Vs Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis	45	Jul 2025
NCT06457698	Temporomandibular Bioviscosupplementation (Platelet-Rich Plasma Combined With Hyaluronic Acid) After Double-Puncture Arthrocentesis: a Randomized Controlled Trial	50 (actual)	Dec 2024
NCT06530745	Quintuple Intra-Articular Hyaluronic Acid (HA) Improves and Platelet-Rich Plasma (PRP) Does Not Affect Mandibular Mobility in TemporomandibularJoint (TMJ) Disorders: A Controlled Trial	78	Jun 2025
NCT05989217	Conservative Therapies in the Treatment of Temporomandibular Disorders: A Randomized Controlled Clinical Trial	96	Sep 2024
NCT04936945	Comparative Study Between the Outcome of Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Arthroscopic Management of Temporomandibular Degenerative Joint Diseases: A Randomized Clinical Trial	20	Jun 2023
NCT04884763 ^a	A Randomized, Double Blind, Placebo-Controlled Single Center Phase 2 Pilot Study to Assess the Safety and Efficacy of Off-label Subcutaneous Administration of Erenumab-	39 (actual)	Jan 2024

	aooe in Patients with Temporomandibular Disorder		
NCT04726683	Trigger Point Dry Needling vs Injection in Patients With Temporomandibular Disorders: a Randomized Placebo-controlled Trial	64	Dec 2024
NCT04298554	Comparison of Cannabinoids to Placebo in Management of Arthralgia and Myofascial Pain Disorder of the Temporomandibular Region: A Randomized Clinical Trial.	59	May 2022
NCT05027243	Outcomes of Bilateral Temporomandibular Joint Arthroscopy and the Role of a Second Intervention - Timings and Results	46	Jul 2021

NCT: national clinical trial.

^a Denotes industry sponsored or co-sponsored trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	20550, 20605, 20606, 21010, 21050, 21060, 21070, 21073, 21076, 21081, 21085, 21089, 21110, 21116, 21120, 21121, 21122, 21123, 21141, 21142, 21143, 21145, 21146, 21147, 21193, 21194, 21195, 21196, 21198, 21199, 21240, 21242, 21243, 21480, 21485, 21490, 29800, 29804, 64553, 64555, 70100, 70110, 70140, 70150, 70220, 70250, 70260, 70300, 70310, 70320, 70328, 70330, 70332, 70336, 70350, 70355, 70360, 70486, 70487, 70488, 76100, 76120, 76125, 76496, 76999, 77077, 78300, 78305, 78306, 78315, 95851, 95867, 95868, 95927, 95937, 97010, 97014, 97024, 97026, 97032, 97033, 97035, 97140, 97530, 97535, 98925, 98943
HCPCS Codes	E0746, E1700, E1701, E1702

*Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.

References

1. Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the

- International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache. 2014; 28(1):6-27. PMID 24482784
2. Ohrbach R, Turner JA, Sherman JJ, et al. The Research Diagnostic Criteria for Temporomandibular Disorders. IV: evaluation of psychometric properties of the Axis II measures. J Orofac Pain. 2010; 24(1):48-62. PMID 20213031
 3. Schiffman E, Ohrbach R. Executive summary of the Diagnostic Criteria for Temporomandibular Disorders for clinical and research applications. J Am Dent Assoc. Jun 2016; 147(6):438-445. PMID 26922248
 4. Almeida FT, Pacheco-Pereira C, Flores-Mir C, et al. Diagnostic ultrasound assessment of temporomandibular joints: a systematic review and meta-analysis. Dentomaxillofac Radiol. Feb 2019; 48(2):20180144. PMID 30285469
 5. Manfredini D, Guarda-Nardini L. Ultrasonography of the temporomandibular joint: a literature review. IntJ Oral Maxillofac Surg. Dec 2009; 38(12):1229-1236. PMID 19700262
 6. Klasser GD, Okeson JP. The clinical usefulness of surface electromyography in the diagnosis and treatment of temporomandibular disorders. J Am Dent Assoc. Jun 2006; 137(6):763-771. PMID16803805
 7. Sharma S, Crow HC, McCall WD, et al. Systematic review of reliability and diagnostic validity of joint vibration analysis for diagnosis of temporomandibular disorders. J Orofac Pain. 2013; 27(1):51-60. PMID 23424720
 8. List T, Axelsson S. Management of TMD: evidence from systematic reviews and meta-analyses. J Oral Rehabil. May 2010; 37(6):430-451. PMID 20438615
 9. Yao L, Sadeghirad B, Li M, et al. Management of chronic pain secondary to temporomandibular disorders: a systematic review and network meta-analysis of randomised trials. BMJ. Dec 15 2023; 383:e076226. PMID 38101924
 10. Friction J, Look JO, Wright E, et al. Systematic review and meta-analysis of randomized controlled trials evaluating intraoral orthopedic appliances for temporomandibular disorders. J Orofac Pain. 2010; 24(3):237-254. PMID 20664825
 11. Ivorra-Carbonell L, Montiel-Company JM, Almerich-Silla JM, et al. Impact of functional mandibular advancement appliances on the temporomandibular joint-a systematic review. Med Oral Patol Oral Cir Bucal. Sep 01 2016; 21(5):e565-572. PMID 27475694
 12. Randhawa K, Bohay R, Côté P, et al. The Effectiveness of Noninvasive Interventions for Temporomandibular Disorders: A Systematic Review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Clin J Pain. Mar 2016; 32(3):260-278. PMID 25924094
 13. Singh BP, Singh N, Jayaraman S, et al. Occlusal interventions for managing temporomandibular disorders. Cochrane Database Syst Rev. Sep 16 2024; 9(9):CD012850. PMID 39282765
 14. Ebrahim S, Montoya L, Busse JW, et al. The effectiveness of splint therapy in patients with temporomandibular disorders: a systematic review and meta-analysis. J Am Dent Assoc. Aug 2012; 143(8):847-857. PMID 22855899
 15. Zhang C, Wu JY, Deng DL, et al. Efficacy of splint therapy for the management of temporomandibular disorders: a meta-analysis. Oncotarget. Dec 20 2016; 7(51):84043-84053. PMID 27823980

16. Riley P, Glenny AM, Worthington HV, et al. Oral splints for temporomandibular disorder or bruxism: a systematic review. *Br Dent J.* Feb 2020; 228(3):191-197. PMID 32060462
17. Al-Moraissi EA, Farea R, Qasem KA, et al. Effectiveness of occlusal splint therapy in the management of temporomandibular disorders: network meta-analysis of randomized controlled trials. *Int J Oral Maxillofac Surg.* Aug 2020; 49(8):1042-1056. PMID 31982236
18. Zhang L, Xu L, Wu D, et al. Effectiveness of exercise therapy versus occlusal splint therapy for the treatment of painful temporomandibular disorders: a systematic review and meta-analysis. *Ann Palliat Med.* Jun 2021; 10(6):6122-6132. PMID 33977737
19. Alajbeg IZ, Vrbanić E, Lapić I, et al. Effect of occlusal splint on oxidative stress markers and psychological aspects of chronic temporomandibular pain: a randomized controlled trial. *Sci Rep.* Jul 03 2020; 10(1):10981. PMID 32620810
20. Melo RA, de Resende CMBM, Rêgo CRF, et al. Conservative therapies to treat pain and anxiety associated with temporomandibular disorders: a randomized clinical trial. *Int Dent J.* Aug 2020; 70(4):245-253. PMID 32153038
21. Ram HK, Shah DN. Comparative evaluation of occlusal splint therapy and muscle energy technique in the management of temporomandibular disorders: A randomized controlled clinical trial. *J Indian Prosthodont Soc.* 2021; 21(4):356-365. PMID 34810363
22. Tonlorenzi D, Brunelli M, Conti M, et al. An observational study of the effects of using a high oral splint on pain control. *Arch Ital Biol.* Sep 30 2019; 157(2-3):66-75. PMID 31821530
23. Häggman-Henrikson B, Alstergren P, Davidson T, et al. Pharmacological treatment of oro-facial pain - health technology assessment including a systematic review with network meta-analysis. *J Oral Rehabil.* Oct 2017; 44(10):800-826. PMID 28884860
24. Mena M, Dalbah L, Levi L, et al. Efficacy of topical interventions for temporomandibular disorders compared to placebo or control therapy: a systematic review with meta-analysis. *J Dent Anesth Pain Med.* Dec 2020; 20(6):337-356. PMID 33409363
25. Machado D, Martimbianco ALC, Bussadori SK, et al. Botulinum Toxin Type A for Painful Temporomandibular Disorders: Systematic Review and Meta-Analysis. *J Pain.* 2020; 21(3-4):281-293. PMID 31513934
26. Isacsson G, Schumann M, Nohlert E, et al. Pain relief following a single-dose intra-articular injection of methylprednisolone in the temporomandibular joint arthralgia - A multicentre randomised controlled trial. *J Oral Rehabil.* Jan 2019; 46(1):5-13. PMID 30240024
27. Tchivileva IE, Hadgraft H, Lim PF, et al. Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial. *Pain.* Aug 2020; 161(8):1755-1767. PMID 32701836
28. Jung A, Shin BC, Lee MS, et al. Acupuncture for treating temporomandibular joint disorders: a systematic review and meta-analysis of randomized, sham-controlled trials. *J Dent.* May 2011; 39(5):341-350. PMID 21354460
29. Liu GF, Gao Z, Liu ZN, et al. Effects of Warm Needle Acupuncture on Temporomandibular Joint Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Evid Based Complement Alternat Med.* 2021; 2021:6868625. PMID 34873409
30. Park EY, Cho JH, Lee SH, et al. Is acupuncture an effective treatment for temporomandibular disorder? A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore).* Sep 22 2023; 102(38):e34950. PMID 37746950

31. Manfredini D, Piccotti F, Guarda-Nardini L. Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature. *Cranio*. Jul 2010; 28(3):166-176. PMID 20806734
32. Machado E, Bonotto D, Cunali PA. Intra-articular injections with corticosteroids and sodium hyaluronate for treating temporomandibular joint disorders: a systematic review. *Dental Press J Orthod*. 2013; 18(5):128-133. PMID 24352399
33. Goiato MC, da Silva EV, de Medeiros RA, et al. Are intra-articular injections of hyaluronic acid effective for the treatment of temporomandibular disorders? A systematic review. *Int J Oral Maxillofac Surg*. Dec 2016; 45(12):1531-1537. PMID 27374020
34. Liu Y, Wu J, Fei W, et al. Is There a Difference in Intra-Articular Injections of Corticosteroids, Hyaluronate, or Placebo for Temporomandibular Osteoarthritis? *J Oral Maxillofac Surg*. Mar 2018; 76(3):504-514. PMID 29182905
35. Gorrela H, Prameela J, Srinivas G, et al. Efficacy of Temporomandibular Joint Arthrocentesis with Sodium Hyaluronate in the Management of Temporomandibular Joint Disorders: A Prospective Randomized Control Trial. *J Maxillofac Oral Surg*. Dec 2017; 16(4):479-484. PMID 29038631
36. Manfredini D, Rancitelli D, Ferronato G, et al. Arthrocentesis with or without additional drugs in temporomandibular joint inflammatory-degenerative disease: comparison of six treatment protocols*. *J Oral Rehabil*. Apr 2012; 39(4):245-251. PMID 21999138
37. Bjørnland T, Gjaerum AA, Møystad A. Osteoarthritis of the temporomandibular joint: an evaluation of the effects and complications of corticosteroid injection compared with injection with sodium hyaluronate. *J Oral Rehabil*. Aug 2007; 34(8):583-589. PMID 17650168
38. Bertolami CN, Gay T, Clark GT, et al. Use of sodium hyaluronate in treating temporomandibular joint disorders: a randomized, double-blind, placebo-controlled clinical trial. *J Oral Maxillofac Surg*. Mar 1993; 51(3):232-242. PMID 8445463
39. Li J, Chen H. Intra-articular injection of platelet-rich plasma vs hyaluronic acid as an adjunct to TMJ arthrocentesis: A systematic review and meta-analysis. *J Stomatol Oral Maxillofac Surg*. Nov 03 2023; 125(2):101676. PMID 37923134
40. Xu J, Ren H, Zhao S, et al. Comparative effectiveness of hyaluronic acid, platelet-rich plasma, and platelet-rich fibrin in treating temporomandibular disorders: a systematic review and network meta-analysis. *Head Face Med*. Aug 26 2023; 19(1):39. PMID 37633896
41. Al-Hamed FS, Hijazi A, Gao Q, et al. Platelet Concentrate Treatments for Temporomandibular Disorders: A Systematic Review and Meta-analysis. *JDR Clin Trans Res*. Apr 2021; 6(2):174-183. PMID32464073
42. Liu SS, Xu LL, Liu LK, et al. Platelet-rich plasma therapy for temporomandibular joint osteoarthritis: A randomized controlled trial. *J Craniomaxillofac Surg*. Nov 2023; 51(11):668-674. PMID 37852892
43. Dasukil S, Arora G, Boyina KK, et al. Intra-articular injection of hyaluronic acid versus platelet-rich plasma following single puncture arthrocentesis for the management of internal derangement of TMJ: A double-blinded randomised controlled trial. *J Craniomaxillofac Surg*. Nov 2022; 50(11):825-830. PMID 36372680
44. Gokçe Kutuk S, Gökçe G, Arslan M, et al. Clinical and Radiological Comparison of Effects of Platelet-Rich Plasma, Hyaluronic Acid, and Corticosteroid Injections on Temporomandibular Joint Osteoarthritis. *J Craniofac Surg*. Jun 2019; 30(4):1144-1148. PMID 31166260

45. Hegab AF, Hameed HIAA, Hassaneen AM, et al. Synergistic effect of platelet rich plasma with hyaluronic acid injection following arthrocentesis to reduce pain and improve function in TMJ osteoarthritis. *J Stomatol Oral Maxillofac Surg*. Feb 2023; 124(1S):101340. PMID 36414172
46. Sit RW, Reeves KD, Zhong CC, et al. Efficacy of hypertonic dextrose injection (prolotherapy) in temporomandibular joint dysfunction: a systematic review and meta-analysis. *Sci Rep*. Jul 19 2021; 11(1):14638. PMID 34282199
47. Haggag MA, Al-Belasy FA, Said Ahmed WM. Dextrose prolotherapy for pain and dysfunction of the TMJ reducible disc displacement: A randomized, double-blind clinical study. *J Craniomaxillofac Surg*. May 2022; 50(5):426-431. PMID 35501215
48. Vos LM, Huddleston Slater JJ, Stegenga B. Lavage therapy versus nonsurgical therapy for the treatment of arthralgia of the temporomandibular joint: a systematic review of randomized controlled trials. *J Orofac Pain*. 2013; 27(2):171-179. PMID 23630689
49. Al-Moraissi EA, Wolford LM, Ellis E, et al. The hierarchy of different treatments for arthrogenous temporomandibular disorders: A network meta-analysis of randomized clinical trials. *J Craniomaxillofac Surg*. Jan 2020; 48(1):9-23. PMID 31870713
50. Hu Y, Liu S, Fang F. Arthrocentesis vs conservative therapy for the management of TMJ disorders: A systematic review and meta-analysis. *J Stomatol Oral Maxillofac Surg*. Feb 2023; 124(1S):101283. PMID 36084892
51. Thorpe ARDS, Haddad Y, Hsu J. A systematic review and meta-analysis of randomized controlled trials comparing arthrocentesis with conservative management for painful temporomandibular joint disorder. *Int J Oral Maxillofac Surg*. Aug 2023; 52(8):889-896. PMID 36732095
52. Hossameldin RH, McCain JP. Outcomes of office-based temporomandibular joint arthroscopy: a 5-yearretrospective study. *Int J Oral Maxillofac Surg*. Jan 2018; 47(1):90-97. PMID 28751180
53. American Association for Dental, Oral, and Craniofacial Research (AADOCR). Science Policy: Temporomandibular disorders (TMD). 1996 (revised 2010, reaffirmed 2015); Available at <<https://www.iadr.org>> (accessed December 13, 2024).
54. American Society of Temporomandibular Joint Surgeons. Guidelines for diagnosis and management of disorders involving the temporomandibular joint and related musculoskeletal structures. *Cranio*. Jan 2003; 21(1):68-76. PMID 12555934
55. Busse JW, Casassus R, Carrasco-Labra A, et al. Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline. *BMJ*. Dec 15 2023; 383:e076227. PMID 38101929
56. American Association of Oral and Maxillofacial Surgeons (AAOMS), Parameters of Care, Clinical Practice Guidelines for Oral and Maxillofacial Surgery. Temporomandibular Joint Surgery (2023). Available at <<https://aaoms.org>> (accessed December 8, 2025).
57. American Association of Oral and Maxillofacial Surgeons (AAOMS), Position Paper. The Contemporary Management of Temporomandibular Joint and Intra-Articular Pain and Dysfunction (2024). Available at <<https://aaoms.org>> (accessed December 8, 2025).
58. American Association of Oral and Maxillofacial Surgeons (AAOMS), Clinical Paper. Reconstructive Oral and Maxillofacial Surgery (2024). Available at <<https://aaoms.org>> (accessed December 8, 2025).

59. NHS England Getting It Right First Time (GIRFT) and Royal College of Surgeons' Faculty of Dental Surgery. Management of painful Temporomandibular disorder in adults (Version 1.1 August 27, 2025). Available at <<https://rcseng.ac.uk>> (accessed December 8, 2025).

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <<https://www.cms.hhs.gov>>.

Policy History/Revision

Date	Description of Change
01/01/2026	Document updated. The following changes were made to Coverage: 1) Significantly revised coverage, including editorial changes to coverage and removal of multiple criteria throughout; 2) Added criteria to diagnostic experimental, investigational and/or unproven section: "computerized mandibular scan" and "arthroscopy of the TMJ for purely diagnostic purposes", 3) Added the following to non-surgical treatment experimental, investigational, and/or unproven statement: "devices promoted to maintain joint range of motion and to develop muscles involved in jaw function"; 4) Removed arthrocentesis from surgical procedures for the treatment of TMJ, addressed under arthroscopic procedures section; and 5) Added the following statement: "Genioplasty may sometimes be performed for cosmetic purposes. Please refer to Medical Policy SUR716.001 Cosmetic and Reconstructive Procedures." References 1-3 and 13 were added; others removed. Title changed from "Temporomandibular Joint (TMJ) Disorders (TMJD)."
07/01/2024	Document updated with literature review. The following changes were made to Coverage: Acupuncture, hyaluronic acid, dextrose prolotherapy and Botulinum toxin A were added to the non-surgical treatments that are considered experimental, investigational, and/or unproven for treatment of temporomandibular joint disorders. Devices promoted to maintain joint range of motion and to develop muscles involved in jaw function was removed from the non-surgical treatments that are considered experimental, investigational and/or unproven for treatment of temporomandibular joint disorders. References 4-7, 9-51, and 54 were added; others removed.

02/01/2024	Document updated with literature review. Coverage unchanged. Reference 5 added and some updated.
10/01/2022	Reviewed. No changes.
04/15/2022	Document updated with literature review. The following change was made to Coverage: Platelet concentrates were added to the non-surgical treatments that are considered experimental, investigational, and/or unproven for treatment of temporomandibular joint disorders. Reference 19 added; some updated and others removed.
08/15/2020	Reviewed. No changes.
08/01/2019	Document updated with literature review. The following change was made to Coverage: Treatment-Surgical section combined the second and third bullet. References 1-2, 4-5, and 14 were added and some references removed.
07/15/2017	Reviewed. No changes.
09/15/2016	Document updated with literature review. The following has been added to the coverage section: Oral devices to prevent TMJ disorders are considered experimental, investigational and/or unproven.
02/01/2016	Reviewed. No changes.
04/15/2014	Document updated with literature review. Coverage unchanged.
07/01/2011	CPT/HCPCS code(s) updated.
10/15/2008	Policy reviewed without literature review; new review date only.
09/15/2007	Coverage revised
05/01/2006	Revised/Updated Entire Document
11/01/1999	Revised/Updated Entire Document
04/01/1999	Revised/Updated Entire Document
09/01/1996	Revised/Updated Entire Document
05/01/1996	Revised/Updated Entire Document
10/01/1993	Revised/Updated Entire Document
01/01/1993	Revised/Updated Entire Document
09/01/1990	New medical document